

Original articles:

1. Changes in hepatic tissue water content in EC-, UW-, and HTK-preserved livers tested in a pig liver transplant model
R. Steininger, E. Roth, P. Holz Müller, H. Reckendorfer, M. Sperlich, **T. Gruenberger**, E. Moser, F. Mühlbacher
Transplantation Proceedings 1991; 23(5): 2414
2. Comparison of HTK- and UW- solution for liver preservation tested in an olt model in the pig
R. Steininger, E. Roth, P. Holz Müller, H. Reckendorfer, **T. Gruenberger**, M. Sperlich, H. Burgmann, E. Moser, W. Feigl, M. Mühlbacher
Transplant International 1992; 5: 403
3. The impact of donor age on graft function in living related kidney transplantation
F. Längle, T. Sautner, **T. Gruenberger**, P. Götzinger, F. Mühlbacher
Transplantation Proceedings 1992; 24(6): 2725
4. Die UW-Lösung in der Organkonservierung für die orthotope Lebertransplantation
R. Steininger, F. Mühlbacher, E. Roth, **T. Gruenberger**, P. Götzinger, P. Wamser, F. Längle, H. Reckendorfer, M. Sperlich
Acta Chirurgica Austriaca 1992; 24: 231-236
5. Impact of vesicoureteral reflux on graft survival in renal transplantation
T. Gruenberger, M. Gnant, T. Sautner, K. Höberth, R. Steininger, J. Hofbauer, F. Mühlbacher
Transplantation Proceedings 1993; 25(1): 1058
6. Impact of donor criteria on postoperative graft function in liver transplantation
Th. Gruenberger, R. Steininger, M. Mittlböck, Th. Sautner, P. Wamser, F. Mühlbacher
Transplantation Proceedings 1993; 25(6): 3156

7. Value of serum soluble tumour necrosis factor concentration in the diagnosis and prognosis of renal graft rejection
M. Keil, M.K. Pec, G. Schenn, **Th. Gruenberger**, G. Kramer,
R. Függer, R. Steininger, F. Mühlbacher, P. Balke, F. Stockenhuber
Nephro Dial Transplant 1994; 9(7): 815-819
8. Andrologic status before and after liver transplantation
S. Madersbacher, **Th. Gruenberger**, U. Maier
J. of Urology 1994; 151(5): 1251-4
9. L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft; influence on nitric oxide metabolism
E. Roth, R. Steininger, S. Winkler, F. Längle, **Th. Gruenberger**,
R. Függer, F. Mühlbacher
Transplantation 1994; 57(5): 665
10. Transhepatic metabolism of TNF- α , IL-6 and Endotoxin in the early hepatic reperfusion period after human liver transplantation
R. Steininger, E. Roth, R. Függer, S. Winkler, F. Längle,
Th. Gruenberger, P. Götzinger, F. Mühlbacher
Transplantation 1994, 58(2): 179-83
11. Influence of donor criteria on postoperative graft function after oLTX
Th. Gruenberger, R. Steininger, Th. Sautner, M. Mittlböck,
F. Mühlbacher
Transplant International 1994; 7(Supp1): 672
12. Kann man einer hochselektionierten Patientinnengruppe nach brusterhaltender Therapie wegen Mammakarzinoms die postoperative Nachbestrahlung ersparen?
Th. Gruenberger, M. Gorlitzer, Th. Soliman, M. Rudas,
M. Mittlböck, P. Götzinger, M. Gnant, A. Reiner, B. Teleky,
W. Seitz, R. Jakesz
Acta Chirurgica Austriaca 1995; 27(5/6): 269-273
13. Tumor recurrence after oLTX
Th. Gruenberger, Th. Windhager, M. Gnant, M. Mittlböck,
R. Steininger, F. Herbst, F. Mühlbacher
Transplant International 1996; 9(Sup1): S151

14. Prediction of graft dysfunction by analysis of liver biopsies after cold storage
Th. Gruenberger, S. Winkler, F. Garro, M. Barlan, W. Huber, E. Roth, R. Steininger, F. Mühlbacher
Transplant International 1996; 9(Sup1): S132
15. The impact of liver transplantation on endocrine status in men
St. Madersbacher, G. Ludvik, Th. Stulnig, **Th. Gruenberger**, U. Maier
Clinical Endocrinology 1996; 44: 461-466
16. Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-Arginine during the early reperfusion period in pig liver transplantation
F. Längle, R. Steininger, E. Waldmann, **Th. Gruenberger**, H. Benditte, M. Mittlböck, Th. Soliman, M. Schindl, U. Windberger, F. Mühlbacher, E. Roth
Transplantation 1997; 63: 1225-1233
17. Late ureteral obstruction after kidney transplantation
U. Maier, S. Madersbacher, S. Banyai-Falger, M. Susani, **Th. Gruenberger**
Transplant International 1997; 10: 65-68
18. Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients
R. Jakesz, H. Salmonigg, M. Gnant, E. Kubista, P. Steindorfer, H. Hausmaninger, P. Sevelda, B. Tschurtschenthaler, M. Fridrik, M. Stierer, R. Kolb, G. Steger and the **Austrian Breast Cancer Study Group**
European Journal of Cancer 1998; 34/1: 66-70
19. It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients
Th. Gruenberger, M. Gorlitzer, T. Soliman, M. Rudas, M. Mittlböck, M. Gnant, A. Reiner, B. Teleky, Seitz, R. Jakesz
Breast Cancer Research and Treatment 1998; 50: 37-46
20. Liver resection and transplantation - therapeutic concepts in surgical treatment of hepatic metastases
R. Steininger, **Th. Gruenberger**
Acta Chirurgica Austriaca 1998; 30: 206-210

21. Preservation of the liver- is it possible to extend the time of storage?
H. Pokorny, **Th. Gruenberger**, S. Rockenschaub, H. Puhalla, F. Mühlbacher,
R. Steininger
Transplantation Proceedings 1999; 31/5: 2074-76
22. First experiences with mesh wrapping for parenchymal liver injuries in orthotopic liver transplantation (OLT)
Th. Soliman, H. Pokorny, S. Rockenschaub, H. Puhalla, **T. Gruenberger**,
M. Schindl, F. Längle, G. Berlakovich, F. Mühlbacher, R. Steininger
Transplantation Proceedings 1999; 31(1-2): 538-9
23. Immunomodulated effects of glycine in LPS-treated monocytes: reduced TNF- α production and accelerated IL-10 expression
A. Spittler, CM. Reissner, R. Oehler, A. Gornikiewicz, **Th. Gruenberger**,
N. Manhart, T. Brodowicz, M. Mittlboeck, G. Boltz-Nitulescu, E. Roth
FASEB Journal 1999; 13: 563-571
24. Randomized trial of low-dose chemotherapy added to Tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
R. Jakesz, H. Hausmaninger, K. Haider, E. Kubista, H. Salmonigg, M. Gnant, D. Manfreda, G. Tschurtschenthaler, R. Kolb, M. Stierer, M. Fridrik, B. Mlineritsch, P. Steindorfer, M. Mittlboeck, G. Steger, and **the Austrian Breast Cancer Study Group**
Journal of Clinical Oncology 1999; 17/6: 1701-1709
25. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
E. Kucera, P. Speiser, M. Gnant, L. Szabo, H. Samonigg, H. Hausmaninger, M. Mittlboeck, M. Fridrik, M. Seifert, E. Kubista, A. Reiner, R. Zeillinger, R. Jakesz and **the Austrian Breast Cancer Study Group**
European Journal of Cancer 1999; 35/3: 398-405
26. Management of organ donation following trauma in conventional heart-beating donor and non-heart-beating donor situations
H. Pokorny, H. Puhalla, CG. Krenn, T. Soliman, F. Langer, **Th. Gruenberger**, B. Gollackner, M. Schindl, P. Wamser, P. Goetzinger, T. Sautner, MF. Gnant, R. Steininger, F. Muehlbacher
Trauma Care 1999; 9/1: 30-32

27. Organ survival after primary dysfunction of liver grafts in clinical oLT
H. Pokorny, **Th. Gruenberger**, T. Soliman, S. Rockenschaub, F. Längle, R. Steininger
Transplant International, 2000;13 Suppl 1:S154-7
 28. Parenchymal liver injuries in orthotopic liver transplantation
T. Soliman, F. Langer, H. Puhalla, H. Pokorny, **Th. Gruenberger**, G.A. Berlakovich, R. Steininger and F. Mühlbacher
Transplantation 2000;69(10):2079-84
- Echogenicity of liver metastases is an independent prognostic factor after potentially curative treatment
Th. Gruenberger, JL. Jourdan, J. Zhao, J. King, DL. Morris
Archives of Surgery 2000; 135(11): 1285-90
29. Reduction in recurrence risk for involved or inadequate margins with edge cryotherapy after liver resection for colorectal metastases
Th. Gruenberger, JL. Jourdan, J. Zhao, J. King, DL. Morris
Arch Surg. 2001 Oct;136(10):1154-7
 31. Extending the limits for curative liver resections by portal vein embolisation
KS. Haghighi, D. Glenn, **Th. Gruenberger**, DL. Morris
Int Surg. 2009 Jan-Feb;94(1):43-7.
 32. Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy
Gruenberger T, Zhao J, King J, Chung T, Clingan PR, Morris DL
Cancer 2002 Mar 15;94(6):1753-9
 33. Long-term follow-up of surgically treated gallbladder cancer patients
Puhalla H, Wild T, Bareck E, Pokorny H, Ploner M, Soliman T, Stremitzer S, Depisch D, Laengle F, **Gruenberger T**
Eur J Surg Oncol 2002 Dec;28(8):857-63
 34. Staged treatment of bilobar hepatic metastases from colorectal cancer
Th. Gruenberger, DL. Morris
Eur J Surg. 2002;168(8-9):516-8

35. Alternative regional treatment of resectable and unresectable liver metastases
Th. Gruenberger
Eur Surg 2002,34/6, 337-40
36. Current strategies in the treatment of colorectal cancer liver metastases: aspects of surgical treatment
M. Schindl, **Th. Gruenberger**, F. Längle
Eur Surg 2002, 34/6, 332-6
37. Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma
Morris DL, Jourdan JL, Finlay I, **Gruenberger T**, The MP, Pourgholami MH
Int J Oncol 2002 Oct;21(4):901-6
38. Resection of Hilar Cholangiocarcinomas: Pivotal Prognostic Factors and Impact of Tumor Sclerosis
Puhalla H, **Gruenberger T**, Pokorny H, Soliman T, Wrba F, Sponer U, Winkler T, Ploner M, Raderer M, Steininger R, Muhlbacher F, Laengle F
World J Surg 2003; 27/6: 680-4
39. Mitomycin C in combination with capecitabine or biweekly high dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial
Kornek GV, Schuell B, Laengle F, **Gruenberger T**, Penz M, Karall K, Depisch D, Lang F, Scheithauer W
Ann Oncology 2004, 15, 478-83
40. p53 analyses in gallbladder cancer: comparison of gene analysis versus immunohistochemistry
Puhalla H, Kandioler D, Ludwig C, Filipits M, Wrba F, Laengle F, Jakesz R, **Gruenberger T**
Anticancer Research, 2004, 24, 1201-6
41. Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies
Th. Gruenberger, B. Schuell, H. Puhalla, E. Schwanzer, M. Bodingbauer, F. Laengle, G. Kornek, W. Scheithauer
European Surgery 2004, 36/5; 317-21

42. Anforderungen der Chirurgie an die bildgebende Diagnostik
Th. Gruenberger
Radiologe 2004, 44; 1154-59
43. Treatment and outcome of intrahepatic cholangiocellular carcinoma
H. Puhalla, B. Schuell, H. Pokorny, GA. Kornek, W. Scheithauer, **Th. Gruenberger**
Am J Surgery 2005, 189/2; 173-7
44. Multidetector-CT (MDCT) der Leber
W. Schima, C. Kulinna, A. Ba-Ssalamah, **Th. Gruenberger**
Radiologe 2005, 45/1; 15-23
45. Influence of laparoscopy on survival after surgery for gallbladder carcinoma: a matched-pair analysis
Puhalla, H., **Gruenberger, T.**, Pokorny, H., Ploner, M., Bareck, E., Depisch, D., Zacherl, J., Bischof, G.
European Surgery 2004, 36/6; 350-55
46. Interdisciplinary management of colorectal cancer liver metastases
Th. Gruenberger, B. Gruenberger, A. Becherer, J. Kettenbach, K. Dieckmann, W. Schima
European Surgery 2006, 38/2; 107-11
47. Side effects during chemotherapy predict tumour response in advanced colorectal cancer
B. Schuell, **Th. Gruenberger**, G. Kornek, N. Dworan, D. Depisch, F. Lang, B. Schneeweiss, W. Scheithauer
Britsch Journal of Cancer 2005; 93, 744-48
48. E-Cadherin and β -Catenin expression in normal, inflamed and cancerous gallbladder tissue
H. Puhalla, B. Herberger, A. Soleiman, M. Filipits, F. Laengle, **Th. Gruenberger**, F. Wrba
Anticancer Research 2005; 25, 4249-54
49. Neoadjuvant therapy with Bevacizumab
Th. Gruenberger, B. Gruenberger, W. Scheithauer
Journal Clinical Oncology 2006; 24, 2592-93

50. HER-2/neu protein expression in colorectal cancer
B. Gruenberger, **Th. Gruenberger**, W. Scheithauer, C. Zielinski, F. Wrba
BMC Cancer 2006; 6: 123
51. Selective resection of colorectal liver metastases
D. Tamandl, B. Gruenberger, B. Herberger, S. Schoppmann, M. Bodingbauer, M. Schindl, H. Puhalla, E. Fleischmann, W. Schima, R. Jakesz, F. Laengle, **Th. Gruenberger**
Eur J Surg Oncol 2007; 33:174-82
52. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases
M. Bodingbauer, D. Tamandl, K. Schmid, C. Plank, W. Schima, **Th. Gruenberger**
Br J Surgery 2007; 94(9): 1133-8
53. Expression of p21^{Waf1/Cip1}, p57^{Kip2} and HER2/neu in Patients with Gallbladder Cancer
H Puhalla, F Wrba, D Kandioler, M Lehnert, A Huynh, **T Gruenberger**, D Tamandl, M Filipits
Anticancer Research 2007; 27(3B): 1679-84
54. Activated mTOR is an adverse prognostic factor in patients with biliary tract adenocarcinoma
B. Herberger, H. Puhalla, M. Lehnert, F. Wrba, S. Novak, A. Brandstetter, **Th. Gruenberger**, R. Pirker, M. Filipits
Clin Cancer Research 2007; 13(16): 4795-9
55. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
B. Nordlinger, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulis V, Giuliante F, Glimelius B, Golling M, **Gruenberger T**, Tabernero J, Wasan H, Poston G; on behalf of European Colorectal Metastases Treatment Group
Eur J Cancer 2007; 43(14): 2037-45
56. Post-treatment imaging of liver tumours
W. Schima, A. Ba-Ssalamah, A. Kurturan, M. Schindl, **Th. Gruenberger**
Cancer Imaging 2007; 7: S28-S36

57. Effects of continuous remifentanyl administration on intra-operative subcutaneous tissue oxygen tension
B. Kabon, A. Kugener, **Th. Gruenberger**, M. Niedermayr, E. Fleischmann, M. Freissmuth, A. Kurz
Anaesthesia 2007; 62: 1101-9
58. Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases
D. Tamandl, B. Herberger, B. Gruenberger, S. Schoppmann, H. Puhalla, M. Schindl, W. Schima, R. Jakesz, **Th. Gruenberger**
Surgery 2008; 143(5): 648-57
59. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, **Th. Gruenberger**
Journal Clinical Oncology 2008; 26(11): 1830-5
60. Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance is Sensitive to Systemic Thrombospondin-1 Levels
C. Brostjan, K. Gebhardt, B. Gruenberger, S. Roka, **Th. Gruenberger**
Clin Cancer Research 2008; 14(7): 2065-74
61. Patterns of Hepatotoxicity after Chemotherapy for Colorectal Cancer Liver Metastases
S. Kandutsch, M. Klinger, S. Hacker, F. Wrba, B. Gruenberger, **Th. Gruenberger**
Eur J Surg Oncol. 2008 Nov;34(11):1231-6. Epub 2008 Feb 12
62. Randomized study of perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)
B. Nordlinger, H. Sorbye, B. Glimelius, GJ. Poston, P. M. Schlag, P. Rougier, W. Bechstein, JN. Primrose, ET. Walpole, M. Finch-Jones, D. Jaeck, D. Mirza, RW. Parks, L. Collette, M. Praet, U. Bethe, E. Van Cutsem, W. Scheithauer, **T. Gruenberger**
Lancet 2008; 371(9617): 1007-16

63. Using Bevacizumab and Cetuximab before liver surgery
B. Gruenberger, **Th. Gruenberger**
Current colorectal cancer reports 2008; 4: 126-9
64. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
B. Gruenberger, W. Scheithauer, R. Punzengruber, C. Zielinski, D. Tamandl,
Th. Gruenberger
BMC Cancer 2008; 25/8: 120
65. Consensus on the medical treatment of colon cancer
G. Kornek, W. Scheithauer, R. Anghel, G. Bodoky, F. Ciardiello, T. Ciuleanu, R. Glynne-Jones, **T. Gruenberger**, I. Koza, J. Ocvirk, L. Petruzella, G. Poston, G. Ramadori, W. Schmiegel, S. Segart, J. Taberner, H. Zwierzina, C. Zielinski
Magazine of European Medical Oncology 2008; 1: 79-90
66. Surgery vs surgery and chemotherapy for colorectal liver metastases
B. Nordlinger, **Th. Gruenberger**, H. Sorbye, B. Glimelius, L. Collette
Lancet 2008, 372 (9634): 203
67. Trials on preoperative chemotherapy in resectable colorectal liver metastases need prospective evaluation of predictive factors of response
Th. Gruenberger, B. Gruenberger
J Clin Oncology 2008; 26, 3813
68. Urgent Need for a New Staging System in Advanced Colorectal Cancer.
GJ. Poston, J. Figueras, F. Giulante, G. Nuzzo, AF. Sobrero, JF. Gigot, B. Nordlinger, R. Adam, **T. Gruenberger**, MA. Choti, AJ. Bilchik, EJ. Van Cutsem, JM. Chiang, MI. D'Angelica MI
Journal Clinical Oncology 2008; 26: 4828-33
69. Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma
D. Tamandl, B. Herberger, B. Gruenberger, H. Puhalla, M. Klinger,
Th. Gruenberger
Ann Surg Oncology 2008; 15: 2787-94

70. HB-EGF is a paracrine growth stimulator for early tumor-prestages in inflammation-associated hepatocarcinogenesis
S. Sagmeister, C. Drucker, A. Losert, M. Grusch, A. Daryabeigi, W. Parzefall,
N. Rohr-Udilova, C. Bichler, B. Smedsrod, D. Kandioler,
Th. Gruenberger, F. Wrba, R. Schulte-Hermann, B. Grasl-Kraupp
J Hepatol. 2008 Dec;49(6):955-64. Epub 2008 Oct 7.
71. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
B. Nordlinger, E. Van Cutsem, **Th. Gruenberger**, B. Glimelius,
G. Poston, P. Rougier, A. Sobrero, M. Ychou on behalf of the
European Colorectal Metastases Treatment Group
Ann Oncology 2009 Jun;20(6):985-92. Epub 2009 Jan 19.
72. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
M. Klinger, S. Eipeldauer, S. Hacker, B. Herberger, D. Tamandl, M. Dorfmeister, C. Koelblinger, B. Gruenberger, **Th. Gruenberger**
Eur J Surg Oncol 2009; 35: 515-20
73. Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial
E. Fleischmann, **C. Marschalek, K. Schlemitz, J. Dalton, Th. Gruenberger, F. Herbst, A. Kurz, D. Sessler**
BMC Anaesthesiology 2009; 9: 1
74. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients
D. Tamandl, B. Gruenberger, K. Kaczirek, B. Herberger, **Th. Gruenberger**
J Surg Oncol 2009; 100: 364-71
75. Endo-sponge assisted treatment of anastomotic leakage following colorectal surgery
S. Riss, A. Stift, M. Meier, E. Haiden, **Th. Gruenberger**, M. Bergmann
Colorectal Dis. 2010 Jul;12(7 Online):e104-8. Epub 2009 Apr 13

76. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma
D. Tamandl, K. Kaczirek, B. Gruenberger, C. Koelblinger, J. Maresh, R. Jakesz, **Th. Gruenberger**
Br J Surgery 2009; 96: 919-25
77. [Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.](#)
B. Herberger, W. Berger, H. Puhalla, K. Schmid, S. Novak, A. Brandstetter, C. Pirker **Th. Gruenberger**, M. Filipits
Mol Cancer Ther. 2009 Jun;8(6):1547-56. Epub 2009 Jun 9
78. [The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.](#)
Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, **Gruenberger T**, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C
Ann Oncol. 2009 Jun;20 Suppl 7:vii1-vii6
79. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, **Gruenberger T**, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; On Behalf of the PRECISION V Investigators.
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52. Epub 2009 Nov 12.
80. The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer
Kovar FM, Thallinger C, Marsik CL, Perkmann T, Puhalla H, Haslacher H, Wrba F, Wagner OF, **Gruenberger T**, Endler G.
Wien Klin Wochenschr. 2009;121(19-20):638-43

81. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Folprecht G, **Gruenberger T**, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczyński C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
Lancet Oncol. 2010 Jan;11(1):38-47. Epub 2009 Nov 26.
82. Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX.
Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, **Gruenberger T**.
Ann Surg Oncol. 2010 Aug;17(8):2059-65. Epub 2010 Feb 23
83. [Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?](#)
Kulemann V, Schima W, Tamandl D, Kaczirek K, **Gruenberger T**, Wrba F, Weber M, Ba-Ssalamah A.
Eur J Radiol. 2010 Apr 12. [Epub ahead of print]
84. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study
Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, **Gruenberger T**
Ann Surg. 2010 Jul;252(1):124-30
85. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes
Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, **Gruenberger T**, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C
J Thrombosis and Haemostasis 2010 May 12. [Epub ahead of print]
86. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, **Gruenberger T**, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W,

Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J
Ann Oncol. 2010 Jun;21 Suppl 6:vi1-10

87. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy
Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K,
Gruenberger B, **Gruenberger T**
Ann Surg Oncol. 2010 Sep 16. [Epub ahead of print]
88. Liver Resection for Colorectal Metastases in Presence of Extrahepatic Disease: Results from an International Multi-institutional Analysis
Pulitanò C, Bodingbauer M, Aldrighetti L, de Jong M, Parks R, Castillo F, Schulick R, Wigmore S, Choti M, Garden J, **Gruenberger T**, Pawlik T
Ann Surg Oncol. 2010; accepted
89. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, **Gruenberger T**
Lancet Oncology 2010; in press
90. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing
Krieger PM, Tamandl D, Herberger B, Faybik P, Fleischmann E, Maresch J, **Gruenberger T**
Ann Surg Oncol 2010; accepted